Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177...

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Advanced metastatic prostate cancer presents significant treatment challenges.
• Prostate-specific membrane antigen (PSMA) is a validated target for prostate cancer therapy.
• Radioligand therapy with lutetium-177 (¹⁷⁷Lu)-PSMA has emerged as a promising treatment modality.

Purpose of the Study:

• To review and synthesize the existing literature on predicting factors for treatment response and survival in patients with advanced metastatic prostate cancer receiving ¹⁷⁷Lu-PSMA therapy.
• To evaluate the impact of ¹⁷⁷Lu-PSMA therapy on key clinical and biochemical markers.

Main Methods:

• A comprehensive literature review was conducted.
• Articles published in English within the last 10 years were included.
• Data on biochemical response (PSA levels) and metastatic burden (lymph node, visceral) were extracted and analyzed.

Main Results:

• Treatment with ¹⁷⁷Lu-PSMA demonstrated a positive impact on prostate-specific antigen (PSA) levels, particularly within the first treatment cycle.
• A notable negative impact on lymph node metastasis was observed.
• Further analysis suggested a positive effect on PSA and performance status after multiple cycles, alongside a negative impact on visceral metastasis.

Conclusions:

• ¹⁷⁷Lu-PSMA therapy is beneficial for patients with castration-resistant prostate cancer.
• The treatment effectively reduces PSA levels and metastatic burden, indicating improved therapeutic outcomes.